NCT00722566 - A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma | Biotech Hunter

Enrollment

222

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions

Multiple Myeloma

Interventions

DRUG

VELCADE Administered by subcutaneous injection

Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle

DRUG

VELCADE Administered by intravenous infusion

Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.

Trial Locations (3)

UZ Brussel Department Medical Oncology Laarbeeklaan 101, Brussels

Hôtel DIEU, Service D'Hématologie Place Alexis RICORDEAU, Nantes

Universitätsklinikum Münster Onkologische Ambulanz West Albert-Schweitzer-Str. 33, Münster